D-쓰레오-메틸페니데이트염산염

D-쓰레오-메틸페니데이트염산염
D-쓰레오-메틸페니데이트염산염 구조식 이미지
카스 번호:
19262-68-1
한글명:
D-쓰레오-메틸페니데이트염산염
동의어(한글):
D-쓰레오-메틸페니데이트염산염
상품명:
D-THREO-METHYLPHENIDATE HYDROCHLORIDE
동의어(영문):
D03721;Focalin;Focalin (tn);D-METHYLPHENIDATE;Dexmethylphenidate HCl;d-threo-Methylphenidate;d-threo-Form hydrochloride;DEXMETHYLPHENIDATE HYDROCHLORIDE;Methylphenidate-d6 hydrochloride;DexaMethylphenedate Hydrochloride
CBNumber:
CB8490337
분자식:
C14H20ClNO2
포뮬러 무게:
269.77
MOL 파일:
19262-68-1.mol

D-쓰레오-메틸페니데이트염산염 속성

녹는점
218-220°C
저장 조건
Controlled Substance, -20°C Freezer
용해도
메탄올(약간 용해됨), 물(약간 용해됨)
물리적 상태
고체
물리적 상태
단단한 모양
색상
흰색에서 황백색까지

안전

위험품 표기 Xn
위험 카페고리 넘버 22
RTECS 번호 TM3850000

D-쓰레오-메틸페니데이트염산염 C화학적 특성, 용도, 생산

개요

Dexmethylphenidate, the pharmacologically effective enantiomer of d,l-methyl phenidate (Ritalin?) was developed as an improved treatment for attention deficit hyperactivity disorder (ADHD) in children. Dexmethylphenidate acts via the inhibition of reuptake of dopamine (by binding to dopamine transporter) and nor-adrenaline. It is thought to block dopamine and noradrenaline reuptake into the presynaptic neuron and increase neurotmnsmitter release into the extraneuronal space. Dexmethytphenidate, at half the usual dose of racemic methylphenidate, improved the symptoms of attention deficit hyperactivity disorder to a similar extent to methylphenidate in both home and school settings (SNAP-ADHD scores) at 3 h post dosing. Moreover, some studies showed that dexmethylphenidate has a statistically significant longer duration of action than the racemic form as measured by a behavioral scale at 6 h post dosing compared to placebo. In patients with ADHD, plasma dexmethylphenidate concentrations increased rapidly, reaching a maximum in the fasted state at approximately l-l.5 h post-dose. The mean plasma half-life for dexmethylphenidate is approximately 2.2 h. Dexmethylphenidate is metabolized to d-α-phenyl-piperidine acetic acid, its main urinary metabolite which has negligible pharmacological activity. In vitro studies showed that dexmethylphenidate did not inhibit cytochrome P450 isozymes. Dexmethylphenidate was well tolerated; the most commonly reported adverse events (abdominal pain, headache, anorexia, insomnia) were mild in severity and consistent with those known to be associated with agents containing methylphenidate. Current labeling states that dexmethylphenidate should be administered twice daily with an interval of at least 4 hours between doses. Stimulant medications have been used for over sixty years and remain, until now, the first line pharmacological therapy for children with ADHD, demonstrating effectiveness in roughly 70% of patients.

화학적 성질

White Solid

용도

Controlled substance. CNS stimulant. More potent enantiomer

D-쓰레오-메틸페니데이트염산염 준비 용품 및 원자재

원자재

준비 용품


Copyright 2019 © ChemicalBook. All rights reserved